To evaluate the ongoing safety, tolerability, and efficacy parameters of PRX-102 in adult
Fabry patients who have successfully completed treatment with PRX-102 in studies PB-102-F01
and PB-102-F02. Patients will be enrolled to receive the same dose of PRX-102 (0.2 mg/kg,
1.0 mg/kg, 2.0 mg/kg), as an intravenous infusion every 2 weeks for 24 Months.